Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 9Rectal Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Surgical Wound Infection 3Pancreatic Neoplasms 3Lymphoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Postoperative Complications 1Persistence of Infection With Helicobacter Pylori 1Neutropenia 1Neoplasms 1Mouth Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Lymphoma, Non-Hodgkin 1Leukemia, B-Cell 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Head and Neck Neoplasms 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Febrile Neutropenia 1Familial primary gastric lymphoma 1Dysbiosis 1Diverticulitis 1Colonic Neoplasms 1Anastomotic Leak 1Adenocarcinoma 1

Interventions

Cyclophosphamide 10fludarabine 7Rituximab 6Bendamustine Hydrochloride 5venetoclax 4obinutuzumab 4Lenalidomide 4ofatumumab 3ibrutinib 3fludarabine phosphate 3acalabrutinib 3Vincristine 3Immunotherapy, Adoptive 3pirtobrutinib 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1ricolinostat 1pembrolizumab 1pegaspargase 1nelarabine 1idelalisib 1blinatumomab 1Whole-Body Irradiation 1Prednisolone 1Pentostatin 1Panobinostat 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, B-Cell × Metronidazole × Clear all
NCT01279252 2019-01-25

CLEAR

King's College Hospital NHS Trust

Phase 2 Completed
71 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡